June 29, 2006 -- Biogen Idec and Elan won approval to put multiple sclerosis drug Tysabri back on the European market; Bristol-Myers Squibb won accelerated approval for Sprycel, a leukemia drug; VaxGen sold part of a manufacturing facility for $79 million; Wyeth received an approvable letter for an oral contraceptive; Nabi signed a deal to develop Civacir jointly; Shire and Noven launched Daytrana, their transdermal patch for ADHD; Keryx released positive data on a drug for dialysis patients; Cytokinetics reported positive results on a new cardiac myosin activator; Lexigon Genetics asked for permission to put a memory drug into Phase I trials; Invitrogen licensed stem cell technology from Geron; Auxilium began a Phase III trial of a testosterone replacement film product; and Alexion announced that APEX-AMI did not decrease mortality. The Centient Biotech 200™ was 85 points higher at 3612.90, an increase of 2.4%. More details...
